Promising combo may boost survival in rare ovarian cancer

NCT ID NCT04602377

First seen Jan 06, 2026 · Last updated Apr 30, 2026 · Updated 21 times

Summary

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. About 27 participants aged 12 and older will receive the combination as their first treatment. The goal is to see if more patients achieve complete remission and can benefit from stronger chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Limoges - Hôpital Dupuytren

    RECRUITING

    Limoges, 87042, France

    Contact

  • Centre Georges François Leclerc

    ACTIVE_NOT_RECRUITING

    Dijon, 21079, France

  • Centre Hospitalier Régional Universitaire de Besançon

    ACTIVE_NOT_RECRUITING

    Besançon, 25030, France

  • Centre Hospitalier Universitaire d'Angers

    ACTIVE_NOT_RECRUITING

    Angers, 49933, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

    Contact

  • Centre Oscar Lambret

    ACTIVE_NOT_RECRUITING

    Lille, 59020, France

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

    Contact

  • Hôpital de Hautepierre

    NOT_YET_RECRUITING

    Strasbourg, France

    Contact

  • ICANS - Institut de cancérologie Strasbourg Europe

    RECRUITING

    Strasbourg, 67033, France

    Contact

  • ICM Val d'Aurelle

    WITHDRAWN

    Montpellier, 34298, France

  • ICO - Paul Papin

    RECRUITING

    Angers, 49055, France

    Contact

  • Institut Bergonié

    ACTIVE_NOT_RECRUITING

    Bordeaux, 33076, France

  • Oncopole Claudius Regaud - IUCT Oncopole

    RECRUITING

    Toulouse, 31059, France

    Contact

Conditions

Explore the condition pages connected to this study.